Centered Background Image

Publication(Sort by year)

2025

Administration route-commended concise organ-selective mRNA transfection (ACCOST) by cyclic disulfide-primed short polyethylenimine.[Nano Today]


  • 2025 Aug          -Nano Today-     [DOI:10.1016/j.nantod.2025.102741]

Click here for details

  • Ye, R., Ren, Q., Chang, L., Zhang, S., Deng, C., Cao, L., Shi, M., Lou, B., Meng, F., Du, S., Ren, K., Piao, X., Xu, C.*, Zhong, Z.*

Polymersome-mediated Cbl-b silencing activates T cells against solid tumors.[Biomater. Sci.]

Click here for details


  • 2025 Apr          -Biomater. Sci.-     [DOI:10.1039/D5BM00001G]

  • Cui G, Shao Y, Wang J, Xu C*, Jinping Zhang*, Zhiyuan Zhong*

2024

Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity.[Sci Adv.]

Click here for details


  • 2024 Oct          -Sci Adv.-     [DOI:10.1126/sciadv.adn9961]

  • Fan T#, Xu C# (co-first author), Wu J#, Cai Y, Cao W, Shen H, Zhang M, Zhu H, Yang J, Zhu Z, Ma X, Ren J, Huang L, Li Q, Tang Y, Yu B, Chen C, Xu M, Wang Q, Xu Z, Chen F, Liang S, Zhong Z, Jamroze A, Tang DG, Li H, Dong C.

Conversion of Chemical Drugs into Targeting Ligands on RNA Nanoparticles and Assessing Payload Stoichiometry for Optimal Biodistribution in Cancer Treatment.[RNA NanoMed]

Click here for details


  • 2024 Jan          -RNA NanoMed-     [DOI:10.59566/ISRNN.2024.0101109]

  • Xu C, Yin H, Yudhistira T, Li Z, Binzel D,*Guo P*

2023

Safety, immunogenicity and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: interim report of a Phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos).[EClinicalMedicine]

Click here for details


  • 2023 Dec         -EClinicalMedicine-     [DOI:0.1016/j.eclinm.2023.102372]

  • Yi Fang, Jing-Xin Li, Davone Duangdany, Yang Li, Xi-Lin Guo, Chanthala Phamisith, Ming-Yun Shen, Bo Yu, Bin Luo, Yu-Zhu Wang, Si-Jun Liu, Fan-Fan Zhao, Cong-Cong Xu, Xu-Hui Qiu, Rong-Juan Pei, Jie Wang, Haifa Shen, Wu-Xiang Guan, Hang-Wen Li, Mayfong Mayxay

Safety and Immunogenicity of SW-BIC-213, a Modified COVID-19 Lipo-Polyplex Mrna Vaccine, in Laotian Healthy Adults Aged 18 Years and Above: a Phase 1/2 Trial[Openalex]

Click here for details


  • 2023 Dec         -Openalex-     [DOI:10.1101/2023.09.11.23295344]

  • Chen, Y., Li, J., Duangdany, D., Phamisith, C., Yu, B., Lan, S., Jin, L., Lv, D., Li, Y., Luo, B., Han, P., Wu, J., Wang, Y., Xu, C., Shen, M., Zhao, F., Liu, P., Pei, R., Shen, H., Guan, W., Li, H., Mayxay, M.

circDesign Algorithm for Designing Synthetic Circular RNA.[bioRxiv]

Click here for details


  • 2023 Jul          -bioRxiv-     [DOI:10.1101/2023.07.09.548293v3]

  • Xu, C., Pu, C., Chen, R., Wang, W., Jiang, F., Deng, C., ... & Zhang, L.

Algorithm for optimized mRNA design improves stability and immunogenicity.[Nature]

Click here for details


  • 2023 May         -Nature-     [DOI:10.1038/s41586-023-06127-z]

  • Zhang, H.#, Zhang, L.#, Lin, A. #, Xu, C. # (co-first author), Li, Z., Liu, K., ... & Huang, L.

2021

Regulation of reversible conformational change, size switching, and immunomodulation of RNA nanocubes.[RNA]

Click here for details


  • 2021 Sep         -RNA-     [DOI:10.1261/rna.078718.121. ]

  • Carcache PJ, Guo S, Li H, Zhang K, Xu C, Chiu W, Guo P.

2020

3D RNA nanocage for encapsulation and shielding of hydrophobic biomolecules to improve the in vivo biodistribution.[Nano Research]

Click here for details


  • 2020 Dec         -Nano Research-     [DOI:10.1007/s12274-020-2996-1]

  • Xu, C., Zhang, K., Yin, H., Li, Z., Krasnoslobodtsev, A., Zheng, Z., Ji, Z., Guo, S., Li, S., Chiu, W. and Guo, P.

RNA nanoparticles as rubber for compelling vessel extravasation to enhance tumor targeting and for fast renal excretion to reduce toxicity.[ACS Nano]

Click here for details


  • 2020 Sept         -ACS Nano-     [DOI:10.1021/acsnano.0c04863]

  • Ghimire C, Wang H, Li H, Vieweger M, Xu C, Guo P.

2019

Tuning the size, shape and structure of RNA nanoparticles for favorable cancer targeting and immunostimulation.[WIREs Nanomedicine and Nanobiotechnology]

Click here for details


  • 2019 Aug         -WIREs Nanomedicine and Nanobiotechnology-     [DOI:10.1002/wnan.1582]

  • Guo S., Xu C., Yin H., Hill J., Pi F., Guo P.

Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping.[J Control Release]

Click here for details


  • 2019 Aug         -J Control Release-     [DOI:10.1016/j.jconrel.2019.08.021]

  • Zheng Z, Li Z, Xu C, Guo B, Guo P.

Construction of RNA nanotubes.[Nano Research]

Click here for details


  • 2019 Aug         -Nano Research-     [DOI:10.1007/s12274-019-2463-z]

  • Li H., Wang S., Ji Z., Xu C., Shlyakhtenko L.S. and Guo P.

Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133.[Mol Ther.]

Click here for details


  • 2019 Jul         -Mol Ther.-     [DOI:10.1016/j.ymthe.2019.04.018]

  • Yin H, Xiong G, Guo S, Xu C, Xu R, Guo P, Shu D.

Specific delivery of delta-5-desaturase siRNA via RNA nanoparticles supplemented with dihomo-γ-linolenic acid for colon cancer suppression.[Redox Biol.]

Click here for details


  • 2019 Feb         -Redox Biol.-     [DOI:10.1016/j.redox.2018.101085]

  • Xu Y, Pang L, Wang H, Xu C, Shah H, Guo P, Shu D, Qian SY.

2018

Photo-controlled release of paclitaxel and model drugs from RNA pyramids.[Nano Res.]

Click here for details


  • 2018 Sept         -Nano Res.-     [DOI:10.1007/s12274-018-2174-x]

  • Xu C, Li H, Zhang K, Binzel DW, Yin H, Chiu W, Guo P.

Favorable biodistribution, specific targeting and conditional endosomal escape of RNA nanoparticles in cancer therapy.[Cancer Lett.]

Click here for details


  • 2018 Feb         -Cancer Lett.-     [DOI:10.1016/j.canlet.2017.09.043]

  • Xu C, Haque F, Jasinski DL, Binzel DW, Shu D, Guo P.

2016

Self-Assembled DNA Nanocentipede as Multivalent Drug Carrier for Targeted Delivery.[ACS Appl Mater Interfaces]

Click here for details


  • 2016 Sept         -ACS Appl Mater Interfaces-     [DOI:10.1021/acsami.6b08210]

  • Li W, Yang X, He L, Wang K, Wang Q, Huang J, Liu J, Wu B, Xu C.

Contact us

  • Tel: +86 0512-65886182
  • Email: xucc@suda.edu.cn

Click here for contact details